Humacyte公司宣布普通股公开发行定价-动脉网

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte 等信源发布 2025-03-25 08:49



可切换为仅中文







PDF Version

PDF 版本

DURHAM, N.C.

北卡罗来纳州达勒姆

，

March 25, 2025

2025年3月25日

(GLOBE NEWSWIRE) --

（环球新闻社）——

Humacyte, Inc.

哈马赛特公司

(Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 25,000,000 shares of its common stock at a public offering price of

(Nasdaq: HUMA)，一家处于商业化阶段的生物技术平台公司，致力于大规模开发可普遍植入的生物工程人体组织，今天宣布了其25,000,000股普通股的承销公开发行定价，公开发行价格为每股

$2.00

2.00美元

per share. The aggregate gross proceeds from this offering are expected to be

每股。此次发行的总毛收入预计为

$50 million

5000万美元

, before deducting underwriting discounts and commissions and other offering expenses payable by

，在扣除承销折扣、佣金及其他应支付的发行费用之前

Humacyte

. The closing of the offering is expected to occur on or about

预计此次发行的结束将在或大约在

March 27, 2025

2025年3月27日

, subject to the satisfaction of customary closing conditions. In addition,

，需满足惯例的交割条件。此外，

Humacyte

has granted the underwriters an option for a period of 30 days to purchase up to an additional 3,750,000 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by

授予了承销商一个期限为30天的期权，以公开发行价（扣除承销折扣和佣金后）购买多达额外3,750,000股Humacyte的普通股。所有普通股股份均由

Humacyte

。

TD Cowen

, Barclays and BTIG are acting as joint book-running managers for the offering.

，巴克莱银行和BTIG担任此次发行的联合簿记管理人。

H.C. Wainwright & Co.

and The

和 The

Benchmark Company

基准公司

are acting as lead managers for the offering.

正在担任此次发行的牵头经理人。

Humacyte

intends to use the net proceeds that it will receive from the offering to fund the commercialization of SYMVESS™ in the vascular trauma indication, the development of the product candidates in Humacyte’s pipeline and for working capital and general corporate purposes.

打算将从此次发行中获得的净收益用于资助SYMVESS™在血管创伤适应症中的商业化、Humacyte产品线中候选产品的开发，以及用于营运资金和一般公司用途。

A shelf registration statement on Form S-3 (No. 333-267225) was previously filed with the

之前已提交了表格S-3（编号333-267225）的货架注册声明

Securities and Exchange Commission

证券交易委员会

(the “SEC”) on

（“美国证券交易委员会”）于

September 1, 2022

2022年9月1日

and declared effective by the

并由以下机构宣布生效

SEC

美国证券交易委员会

打开

September 9, 2022

2022年9月9日

. The securities are being offered by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the

证券通过与发行相关的招股说明书补充文件及随附的招股说明书进行发售，这些文件构成注册声明的一部分。与此次发行相关并描述其条款的初步招股说明书补充文件已提交给

SEC

证券交易委员会

打开

March 25, 2025

2025年3月25日

and is available on the SEC’s website at

并且可以在SEC的网站上获取，网址为

www.sec.gov

. The final prospectus supplement relating to and describing the terms of the offering will be filed with the

与发行相关的最终招股说明书补充文件将与描述发行条款的文件一同提交给

SEC

证券交易委员会

and will be available on the SEC’s website at

并且将在SEC的网站上提供，网址为

www.sec.gov

. Before investing in the offering, you should read each of the prospectus supplement and the accompanying prospectus relating to the offering in their entirety as well as the other documents that

在投资本次发行之前，你应该完整阅读与本次发行相关的每一份招股说明书补充文件和随附的招股说明书，以及其他文件。

Humacyte

has filed with the

已提交给

SEC

美国证券交易委员会

that are incorporated by reference in the prospectus supplement and the accompanying prospectus relating to the offering, which provide more information about

通过引用并入招股说明书补充文件和与本次发行相关的附带招股说明书中，提供了更多关于

Humacyte

and the offering. Copies of the final prospectus supplement, when available, and accompanying prospectus relating to the offering may be obtained from

以及发行相关的最终招股说明书补充文件的副本（一旦可用）和随附的招股说明书可从以下途径获取：

TD Securities (USA) LLC

TD证券（美国）有限责任公司

，

1 Vanderbilt Avenue

1范德比尔特大道

，

New York, New York

纽约，纽约州

10017, by telephone at (833) 297-2926, or by email at

10017，电话号码为（833）297-2926，或通过电子邮件

TD.ECM_Prospectus@tdsecurities.com

;

；

Barclays Capital Inc.

巴克莱资本公司

, c/o Broadridge Financial Solutions,

，转交 Broadridge Financial Solutions，

1155 Long Island Avenue

1155 长岛大道

，

Edgewood, New York

纽约州埃奇伍德

11717, by telephone at (888) 603-5847, or by email at

11717，电话号码为（888）603-5847，或通过电子邮件

barclaysprospectus@broadridge.com

巴克莱招股说明书@百瑞达.com

; or

；或者

BTIG, LLC

BTIG有限责任公司

，

65 East 55th Street

65号东55街

，

New York, New York

纽约，纽约州

10022, by telephone at (212) 593-7555 or by email at

10022，电话号码为（212）593-7555，或通过电子邮件

ProspectusDelivery@btig.com

招股说明书交付@btig.com

。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售或征求购买本文所述任何证券的要约，也不得在任何州或地区出售这些证券，若在这些州或地区进行此类要约、征求或出售属于违反当地证券法之前未注册或未取得资格的行为，则不得进行此类出售。

About

关于

Humacyte

Humacyte, Inc.

Humacyte公司

(Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine.

（纳斯达克：HUMA）正在开发一种颠覆性的生物技术平台，以提供可普遍植入的生物工程人类组织、先进的组织构建体和器官系统，旨在改善患者生活并转变医学实践。

Humacyte

develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s initial product candidates, a portfolio of acellular tissue engineered vessels (“ATEVs”), are currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous (“AV”) access for hemodialysis, and peripheral artery disease (“PAD”).

开发和生产无细胞组织，用于治疗多种疾病、损伤和慢性病。Humacyte 的初始产品候选物是一个无细胞组织工程血管（“ATEVs”）组合，目前正处于针对多种血管应用的晚期临床试验阶段，包括血管创伤修复、血液透析的动静脉（“AV”）通路以及外周动脉疾病（“PAD”）。

A Biologics License Application for the ATEV in the vascular trauma indication was approved by the .

针对ATEV在血管创伤适应症的生物制品许可申请已获批准。

U.S. Food and Drug Administration

美国食品药品监督管理局

(“FDA”) in

("FDA") 在

December 2024

2024年12月

. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (“RMAT”) designation and has also received FDA Fast Track designation.

Humacyte公司的6毫米ATEV用于血液透析的动静脉通路，是首个获得FDA再生医学先进疗法（“RMAT”）认定的产品候选者，并且还获得了FDA的快速通道认定。冠状动脉搭桥术、小儿心脏手术、1型糖尿病的治疗以及多种新型细胞和组织应用的临床前开发也在进行中。

Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the .

Humacyte的6毫米ATEV用于肢体血管创伤后的紧急动脉修复以及治疗晚期PAD，也获得了RMAT指定。ATEV还获得了对血管创伤治疗的优先指定。

U.S.

美国

Secretary of Defense.

国防部长。

For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

对于FDA批准的四肢血管创伤适应症以外的用途，ATEV是一种研究性产品，尚未获得FDA或任何其他监管机构的销售批准。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

本新闻稿包含基于信念、假设及当前可获得信息的前瞻性陈述。在某些情况下，您可以通过以下词语识别前瞻性陈述：“可能”、“将”、“可以”、“会”、“应该”、“预期”、“打算”、“计划”、“预见”、“相信”、“估计”、“预测”、“项目”、“潜在”、“继续”、“正在进行”或这些术语的否定形式或其他类似表述，尽管并非所有前瞻性陈述都包含这些词语。

These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although .

这些陈述涉及风险、不确定性和其他可能导致实际结果、活动水平、表现或成就与这些前瞻性陈述明示或暗示的信息有重大差异的因素。尽管如此。

Humacyte

believes that it has a reasonable basis for each forward-looking statement contained in this press release,

相信本新闻稿中包含的每一项前瞻性陈述均有合理的依据，

Humacyte

哈马赛特

cautions you that these statements are based on a combination of facts and factors currently known by it and its projections of the future, about which

警告您，这些声明是基于其已知的事实和因素的组合，以及其对未来的预测，

Humacyte

cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the timing and satisfaction of customary closing conditions of the offering; the anticipated use of proceeds from the offering; Humacyte’s plans and ability to commercialize its ATEV in .

无法确定。本新闻稿中的前瞻性陈述包括但不限于关于发行的时间和满足惯常交割条件的陈述；发行所得款项的预期用途；Humacyte公司计划及其在美国商业化其ATEV的能力。

the United States

美国

under the brand name SYMVESS in vascular trauma repair; the statements regarding the initiation, timing, progress, and results of Humacyte’s preclinical and clinical trials; the anticipated characteristics and performance of its ATEVs; Humacyte’s ability to successfully complete, preclinical and clinical trials for its ATEVs; the anticipated benefits of the ATEV relative to existing alternatives; the anticipated commercialization of the ATEVs and Humacyte’s ability to manufacture at commercial scale; the implementation of Humacyte’s business model and strategic plans for its business; and the timing or likelihood of regulatory filings, acceptances and approvals.

在血管创伤修复领域，品牌名为SYMVESS；关于Humacyte的临床前和临床试验的启动、时间、进展及结果的声明；其ATEV的预期特性与性能；Humacyte成功完成其ATEV临床前和临床试验的能力；ATEV相对于现有替代方案的预期优势；ATEV的预期商业化及Humacyte实现商业规模生产的能力；Humacyte业务模式的实施及其战略计划；以及监管文件提交、接受和批准的时间或可能性。

。

Humacyte

胡玛赛特公司

cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that .

无法向您保证本新闻稿中的前瞻性陈述将会被证明是准确的。这些前瞻性陈述受到许多重大风险和不确定性的制约，可能导致实际结果与预期结果存在重大差异，其中包括适用法律法规的变化、可能性等。

Humacyte

may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those described under the header “Risk Factors” in Humacyte’s Annual Report on Form 10-K for the year ended

可能受到其他经济、商业和/或竞争因素的不利影响，以及其他风险和不确定性的影响，包括Humacyte年度报告Form 10-K中“风险因素”标题下描述的内容，截至本年度结束。

December 31, 2023

2023年12月31日

, Humacyte’s quarterly report on Form 10-Q for the quarter ended

，Humacyte截至季度末的10-Q表季度报告

September 30, 2024

2024年9月30日

, each filed by

，每份由

Humacyte

with the

随着

SEC

证券交易委员会

, and in future

，以及未来

SEC

证券交易委员会

filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by .

备案。这些因素大多不在Humacyte的控制范围内，且难以预测。此外，如果前瞻性声明被证明不准确，其不准确性可能至关重要。鉴于这些前瞻性声明中存在重大不确定性，您不应将这些声明视为一种陈述或保证。

Humacyte

or any other person that

或任何其他人

Humacyte

will achieve its objectives and plans in any specified time frame, or at all. Except as required by law,

将在任何规定的时间内或完全实现其目标和计划。除非法律要求，

Humacyte

has no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing Humacyte’s views as of any date subsequent to the date of this press release.

目前无意更新本新闻稿中的任何前瞻性声明。因此，您不应依赖这些前瞻性声明来代表 Humacyte 在本新闻稿日期之后的任何日期的观点。

Humacyte Investor Contact:

Humacyte 投资者联系人:

Joyce Allaire

乔伊斯·阿拉尔

LifeSci Advisors LLC

生命科学顾问有限责任公司

+1-617-435-6602

jallaire@lifesciadvisors.com

investors@humacyte.com

投资者@humacyte.com

Humacyte Media Contact: